This website will offer limited functionality in this browser. We only support the recent versions of major browsers like Chrome, Firefox, Safari, and Edge.
In recent years, the adoption of advanced treatments in inflammatory bowel disease has evolved. Oral products have captured a significant share in ulcerative colitis, while Skyrizi, a 3rd generation biologic, has gained share in Crohn’s Disease. Despite these newer entrants, 1st generation biologics maintain significant patient share in both diseases.
1 in 4 people globally are already affected by NCDs. By 2030, NCDs will cause 55 million deaths per year under ‘business as usual.’1,2 Effective...
CRA’s Becky Davis examines how these dramatic price reductions, combined with Direct-to-Patient distribution models, may be accelerating employer migration...
